Quick Summary
- Shares of Hims & Hers Health (HIMS) declined approximately 7% on Monday following the disclosure of a $300 million convertible senior notes offering.
- The convertible debt instruments carry a maturity date of June 1, 2032, and will be sold exclusively to qualified institutional investors through a private placement.
- Capital raised will support the company’s global expansion initiatives and help finance the anticipated Eucalyptus acquisition, projected to finalize in mid-2026.
- A portion of the raised funds will be allocated toward capped call arrangements designed to reduce potential shareholder dilution.
- The initial buyers received an over-allotment option allowing them to purchase an additional $45 million in notes during a 13-day window following the initial sale.
Shares of Hims & Hers Health (HIMS) experienced a significant decline of roughly 7% during Monday’s trading session after the digital health company unveiled intentions to secure $300 million through an offering of convertible senior notes maturing in 2032.
Hims & Hers Health, Inc., HIMS
The equity had already retreated close to 4% during pre-market hours following the initial disclosure, with downward pressure intensifying after the opening bell.
The debt securities will be sold through a private placement exclusively targeting qualified institutional investors. Critical terms including the interest rate and conversion ratio will be determined when pricing is finalized.
Coupon payments on these notes will occur twice annually. The instruments reach maturity on June 1, 2032, subject to earlier repurchase, redemption, or conversion.
Bondholders will possess conversion rights that can be exercised under specific circumstances. Upon conversion, Hims & Hers maintains flexibility to settle obligations using cash, Class A common shares, or a combination thereof.
Minimizing Shareholder Dilution Through Capped Calls
The telehealth provider intends to deploy a portion of the capital raised toward implementing capped call transactions. This strategic approach aims to mitigate potential equity dilution facing current Class A shareholders should the notes ultimately convert to common stock.
The initial underwriters secured a 13-day over-allotment provision enabling them to acquire up to an extra $45 million in notes. Should this option be fully executed, the aggregate offering would reach $345 million.
The company gains the ability to redeem these notes beginning June 6, 2029 — though only under conditions where Class A share prices surpass 130% of the conversion price for a specified duration. Additionally, noteholders possess put rights requiring the company to repurchase the notes for cash should certain fundamental corporate changes materialize.
Funding Eucalyptus Deal and Global Market Entry
According to Hims & Hers, the primary objective for these proceeds centers on preserving financial agility to support its international expansion strategy. This particularly includes financing the pending acquisition of Eucalyptus, a telehealth platform based in Australia.
The Eucalyptus transaction is anticipated to reach completion around mid-2026. Complete financial details regarding the acquisition have not been publicly disclosed by the company.
In addition to the acquisition, management indicated plans to channel investments toward technology infrastructure and fulfillment operations. The company also intends to strengthen AI capabilities and expand its integrated data ecosystem.
HIMS shares were trading down approximately 7.7% on Monday according to the most recent market data.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
